Bristol-Myers Squibb(US:BMY)2025-02-06 12:52Financial Performance & Guidance - Bristol-Myers Squibb's (BMS) Q4 2024 total revenues remained consistent with GAAP and Non-GAAP figures, reaching $12.3 billion, and full-year revenues also matched at $48.3 billion[51] - The company projects 2025 total revenues to be approximately $45.5 billion[21, 56] - BMS anticipates Non-GAAP EPS to be in the range of $6.55 to $6.85 for 2025[21, 56] - An expanded strategic productivity initiative is expected to yield incremental cost savings of approximately $2 billion by the end of 2027, with around $1 billion expected in 2025[21, 55] Portfolio Performance - The Growth Portfolio experienced a revenue increase of 21%, or 23% Ex-FX, in Q4 2024[11, 26] - For the full year 2024, the Growth Portfolio's revenue grew by 17%, or 19% Ex-FX[14, 15] - Legacy portfolio revenues were $6 billion in Q4 2024 and $25.7 billion for the full year 2024[12, 15] - Eliquis sales reached $3.195 billion in Q4 2024, representing an 11% year-over-year increase, and $13.333 billion for the full year, a 9% increase[33] Pipeline & Strategic Focus - BMS is focusing on transformational medicines, driving operational effectiveness, and strategically allocating capital to deliver sustained top-tier growth and long-term shareholder returns[23] - The company has a potential for 10+ New Molecular Entities (NMEs) and 30+ major Life Cycle Management (LCM) indications between 2025 and 2030[23] - Cobenfy is identified as having expansion opportunities with potential multi-billion-dollar peak sales over the decade[17]